Clinical Research Directory
Browse clinical research sites, groups, and studies.
First In Human Study of CX-2051 in Advanced Solid Tumors
Sponsor: CytomX Therapeutics
Summary
The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 as a monotherapy and in combination with bevacizumab in adult participants with advanced solid tumors.
Official title: An Investigational Study of CX-2051 in Participants With Advanced Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
160
Start Date
2024-04-02
Completion Date
2029-03-31
Last Updated
2026-03-25
Healthy Volunteers
No
Conditions
Interventions
CX-2051
Investigational drug
Bevacizumab
IV infusion
Locations (5)
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Carolina BioOncology Institute, PLLC
Huntersville, North Carolina, United States
Sarah Cannon Research Institute, LLC
Nashville, Tennessee, United States
START San Antonio LLC
San Antonio, Texas, United States